SAVE-Care Trial: Empagliflozin for Gout and High Uric Acid
The SAVE-Care trial is studying empagliflozin (a drug) to see if it can lower high uric acid levels in people with gout. You might be able to join if you are between 18 and 80 years old, have gout, have had at least one gout flare in the last year, and your uric acid level is 6 mg/dL or higher. Participants will receive either empagliflozin 10 mg daily or a placebo (an inactive pill). The main goal is to see how much empagliflozin changes uric acid levels over three months. This study aims to gather information that could help improve future gout treatment guidelines.
- Study design
- This is a double-blind, randomized, placebo-controlled study with 60 participants. It compares empagliflozin 10mg daily to a placebo.
- What's involved
- Participants will take either empagliflozin or a placebo daily for 12 weeks. Serum urate levels will be measured at the beginning and after three months.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for three months after starting the study.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Hyon K Choi, MD, DrPH · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Serum Urate ChangeScreening to three months of follow-up
Change in serum urate \[SU\] levels as compared with controls at Week 12. SU levels will be obtained at screening and Week 4, 8, and 12.